ZATTARIN, EMMA
ZATTARIN, EMMA
Universita' degli Studi di MILANO
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario
2022 L. Cantini, G. Mentrasti, G.L. Russo, D. Signorelli, G. Pasello, E. Rijavec, M. Russano, L. Antonuzzo, D. Rocco, R. Giusti, V. Adamo, C. Genova, A. Tuzi, A. Morabito, S. Gori, N.L. Verde, R. Chiari, A. Cortellini, V. Cognigni, F. Pecci, A. Indini, A. De Toma, E. Zattarin, S. Oresti, E.G. Pizzutilo, S. Frega, E. Erbetta, A. Galletti, F. Citarella, S. Fancelli, E. Caliman, L. Della Gravara, U. Malapelle, M. Filetti, M. Piras, G. Toscano, L. Zullo, M. De Tursi, P. Di Marino, V. D'Emilio, M.S. Cona, A. Guida, A. Caglio, F. Salerno, G. Spinelli, C. Bennati, F. Morgillo, A. Russo, C. Dellepiane, I. Vallini, V. Sforza, A. Inno, F. Rastelli, V. Tassi, L. Nicolardi, V. Pensieri, R. Emili, E. Roca, A. Migliore, T. Galassi, M.L.B. Rocchi, R. Berardi
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy
2022 A. Prelaj, M. Boeri, A. Robuschi, R. Ferrara, C. Proto, G. Lo Russo, G. Galli, A. De Toma, M. Brambilla, M. Occhipinti, S. Manglaviti, T. Beninato, A. Bottiglieri, G. Massa, E. Zattarin, R. Gallucci, E.G. Galli, M. Ganzinelli, G. Sozzi, F.G.M. de Braud, M.C. Garassino, M. Restelli, A.L.G. Pedrocchi, F. Trovo'
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)
2022 A. Mennitto, E. Zattarin, M. Di Maio, D. Bimbatti, U. De Giorgi, S. Buti, D. Santini, C. Casadei, M. Soraru, C. Messina, C. Mucciarini, G. Di Lorenzo, G. Roviello, C. Buttigliero, M. Stellato, P. Sepe, M. Claps, V. Guadalupi, A. Ottini, S. Pignata, F.G. De Braud, E. Verzoni, G. Procopio
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin
2022 E. Zattarin, F. Nichetti, F. Ligorio, L. Mazzeo, R. Lobefaro, G. Fuca, G. Peverelli, A. Vingiani, G. Bianchi, V, G. Capri, F. de Braud, C. Vernieri
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology
2022 S. Manglaviti, M. Brambilla, D. Signorelli, R. Ferrara, G. Lo Russo, C. Proto, G. Galli, A. De Toma, M. Occhipinti, G. Viscardi, T. Beninato, E. Zattarin, M. Bini, R. Lobefaro, G. Massa, A. Bottiglieri, G. Apollonio, E. Sottotetti, R.M. Di Mauro, B. Trevisan, M. Ganzinelli, A. Fabbri, F.G.M. de Braud, M.C. Garassino, A. Prelaj
Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients
2021 F. Ligorio, L. Zambelli, A. Bottiglieri, L. Castagnoli, E. Zattarin, R. Lobefaro, A. Ottini, A. Vingiani, S.M. Pupa, G.V. Bianchi, G. Capri, G. Pruneri, F. de Braud, C. Vernieri
Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report
2021 E. Zattarin, F. Ligorio, F. Nichetti, G. Bianchi, G. Capri, F. de Braud
Monitoring patients with head and neck cancer for flu-like symptoms during the COVID-19 pandemic
2021 S. Cavalieri, E. Colombo, A. Bottiglieri, G. Massa, F. Platini, A. Ottini, D. Filippini, E. Zattarin, C. Bergamini, C. Resteghini, S. Alfieri, V. Di Martino, V. Tiraferri, L. Locati, L. Licitra
The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (Her2)—positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab
2021 F. Ligorio, G. Fuca, E. Zattarin, R. Lobefaro, L. Zambelli, R. Leporati, C. Rea, G. Mariani, G.V. Bianchi, G. Capri, F. de Braud, C. Vernieri
Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer
2021 F. Ligorio, I. Pellegrini, L. Castagnoli, A. Vingiani, R. Lobefaro, E. Zattarin, M. Santamaria, S.M. Pupa, G. Pruneri, F. de Braud, C. Vernieri
Evaluation of drug-drug interactions in EGFR-mutated non-small-cell lung cancer patients during treatment with tyrosine-kinase inhibitors
2021 M. Occhipinti, M. Brambilla, G. Galli, S. Manglaviti, M. Giammaruco, A. Prelaj, R. Ferrara, A. De Toma, C. Proto, T. Beninato, E. Zattarin, G.L. Russo, A.J. Gelibter, M. Simmaco, R. Preissner, M.C. Garassino, F. De Braud, P. Marchetti
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications
2020 E. Zattarin, R. Leporati, F. Ligorio, R. Lobefaro, A. Vingiani, G. Pruneri, C. Vernieri
Prognostic role of body mass index (BMI) in patients with Human Epidermal growth factor Receptor 2 (HER2)epositive early breast cancer treated with adjuvant trastuzumab-containing chemotherapy
2020 F. Ligorio, L. Zambelli, A. Bottiglieri, L. Castagnoli, E. Zattarin, R. Loberfaro, A. Belfiore, A. Vingiani, G. Pruneri, G. Bianchi, G. Capri, S. Pupa, F. de Braud, C. Vernieri
Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study
2020 E. Zattarin, C. Fabbroni, F. Ligorio, A. Marra, C. Corti, O. Bernocchi, M. Sirico, D. Generali, G. Curigliano, G. Bianchi, G. Capri, L. Rivoltini, F. De Braud, C. Vernieri